According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...
GlobalData on MSN6d
Pfizer reports positive data from prostate cancer combination therapy trialIn the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...
As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...
Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...
A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).
Ahmedabad: Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received ...
On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback